We're pleased to share positive topline data from our 12-week Phase 2a #obesity study of our oral, non-peptide GLP-1 receptor agonist, GSBR-1290, along with positive data from our capsule to tablet PK study. GSBR-1290 demonstrated clinically meaningful and statistically significant weight loss and generally favorable safety and tolerability result. We look forward to starting our Phase 2b study, which is on track to begin in the fourth quarter of this year. Read the full announcement here: https://lnkd.in/eJp_qPuS
Exciting news. Hope the Structure therapeutics partner with a big pharma to speed up the trials and bring the drug to market through regulatory approvals.
Congratulations to the entire global team at Structure Therapeutics!
Good luck at every step of the development process
Impressive! Congratulations to all at Structure. Wish you continued success!
Exciting news! Kudos to the whole team..
Super news. Congrats Robert Gatmaitan Kathy Maloney and the whole team. Pleasure to work with!
Brilliant! all the best for approval soon!
Congratulations, Ray!
Congrats Ray and the Structure Therapeutics team! Exciting stuff and wish you all continued successes!
Aweome, news! Congrats, Jun Yoon & Robert Gatmaitan & team!